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Abstract
RBX1 (also known as ROC1) is a RING subunit of SCF (Skp1, Cullins, F-box proteins) E3 ubiquitin
ligases, required for SCF to direct a timely degradation of diverse substrates, thereby regulating
numerous cellular processes under both physiological and pathological conditions. Previous studies
have shown that RBX1 is essential for growth in yeast, Caenorhabditis elegans and Drosophila. The
role of RBX1 in mouse development and in regulation of cancer cell survival was unknown. Our
recent work demonstrated that RBX1 is an essential gene for mouse embryogenesis, and targeted
disruption of RBX1 causes embryonic lethality at E7.5 due to hypoproliferation as a result of p27
accumulation. We also showed that RBX1 is overexpressed in a number of human cancers, and
siRNA silencing of RBX1 caused cancer cell death as a result of sequential induction of G2-M arrest,
senescence and apoptosis. These findings reveal a physiological role of RBX1 during mouse
development and a pathological role for the survival of human cancer cells. Differential outcomes
between normal (growth arrest) and cancer cells (cell death) upon RBX1 disruption/silencing
suggest RBX1 as a valid anticancer target.
Comments on:
Tan M, Davis SW, Saunders TL, Zhu Y, Sun Y. RBX1/ROC1 disruption results in early embryonic
lethality due to proliferation failure, partially rescued by simultaneous loss of p27. Proc Natl Acad
Sci USA. 2009; 106:6203–6208
Jia L, Soengas MS, Sun Y. ROC1/RBX1 E3 ubiquitin ligase silencing suppresses tumor cell growth
via sequential induction of G2-M arrest, apoptosis, and senescence. Cancer Res. 2009; 69:4974–82
Introduction
SCF (Skp1, Cullins, F-box proteins) E3 ubiquitin ligases,
consist of Skp1, Cullins, F-box proteins, and the RING
domain containing protein RBX1/ROC1 or its family
member RBX2/ROC2/SAG. By promoting degradation of
many short-lived proteins, including cell cycle regulators,
transcription factors and signal transducers, RBX1-SCF E3
ligases regulate many biological processes. As an essential
subunit of the SCF E3 ligase complex, RBX1, is evolution-
arily conserved from plants to mammals with multiple
family members in each species [1]. Human RBX1 gene
consists of five exons and four introns and encodes a 108
amino acids-containing protein with a RING-H2 finger
domain (C3H2C3) at the C-terminus, which is required
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for zinc ion binding and ubiquitin ligation. Human RBX1
is ubiquitously expressed in human tissues with the high-
est expression in heart, skeleton muscle, kidney and pla-
centa [2]. Structurally, RBX1 binds to the C-terminus of
cullin-1 via its N-terminus and to an E2 ubiquitin conju-
gating enzyme via its C-terminal RING domain. RBX1/
Cullin-1 complex catalyzes the ubiquitin transfer from E2
to the substrates which are recognized by different F-box
proteins, linked to the N-terminus of cullin-1 via an adap-
tor protein, Skp1 [3] (Fig 1).
RBX1 binds to all seven cullin family members, including
cullin-1, -2, -3, -4A, -4B, -5 and -7 [4]. By binding to and
interaction with different cullins and cullin-associated
proteins, RBX1, as an active RING component of the larg-
est family of E3 ubiquitin ligases, plays an essential role in
regulation of diverse biological processes by promoting
the degradation of different protein substrates. Table 1
lists some known substrates targeted by different RBX1-
cullins complexes. Over 350 potential RING-cullin sub-
strates were recently identified by a global protein stability
profiling analysis [5]. Further characterization and valida-
tion of these substrates will broaden our understanding of
how RBX1-cullin-based E3 ligases regulate cellular proc-
esses under physiological and pathological conditions.
Discussion
RBX1 in development
RBX1-cullin complexes control the proteolysis of numer-
ous substrates related to cell cycle progression, cell growth
and cell death, suggesting that RBX1 may play an impor-
tant role in development. Indeed, RBX1 is an essential
gene in a number of species. In yeast, deletion of Hrt1, the
yeast homologue of RBX1, via genetic manipulation,
causes yeast death, which can be rescued by human RBX1
or RBX2/SAG [6-8]. In Caenorhabditis elegans, RBX1 is also
crucial for cell cycle progression and chromosome metab-
olism, as evidenced by severe defects in meiosis, mitotic
chromosomal condensation and segregation, and cytoki-
nesis upon siRNA knockdown [9]. In Drosophila, ROC1a,
the drosophila homologue of RBX1 is required for cell
proliferation and embryo development, and deletion of
ROC1a results in animal death [10]. In mouse, the level of
RBX1 mRNA was regulated during embryonic develop-
ment with the strongest expression at embryonic day 7
(E7), followed by a progressive decrease [11]. However,
the physiological role of RBX1 in mouse development has
not been previously characterized.
Most recently, we characterized the in vivo physiological
function of RBX1 during mouse development using a con-
ventional knockout study [12]. We found that
homozygous disruption of mouse RBX1 via a gene trap
strategy causes embryonic lethality at E7.5 as a result of
reduced proliferation, but not enhanced apoptosis. Mech-
anistic studies revealed that RBX1 disruption induces sig-
nificant accumulation of p27, a cyclin dependent kinase
inhibitor, normally not expressed in early embryos. The
p27 accumulation was further observed in mouse embry-
onic fibroblasts (MEF) or mouse embryonic stem cells
(ESC) with RBX1 heterozygous background. In RBX1+/-
MEF cells, p27 accumulation is associated with growth
retardation and G1 arrest. Causal involvement of p27
accumulation in early death of RBX1-deficient embryos
was clearly demonstrated by a rescue experiment in which
simultaneous loss of p27 extends the life span of RBX1-
deficient embryos from E6.5 to E9.5 [12]. Our study dem-
onstrates that the in vivo physiological function of RBX1 is
to ensure cell proliferation by preventing p27 accumula-
tion during the early stage of embryonic development (Fig
2A). The fact that p27 loss cannot completely rescue
RBX1-deficient embryos indicates that accumulation of
other RBX1 substrates upon RBX1 disruption is detrimen-
tal to embryonic development beyond E9.5 (Fig 2A). A
future challenge will be to define these physiologically rel-
evant substrates to broaden our understanding of the in
vivo physiological function of RBX1 in the later stages of
mouse embryogenesis.
Functional characterization using various model systems
from yeast to mouse clearly demonstrated that RBX1 is an
Substrate ubiquitination by RBX1-SCF E3 ubiquitin ligase Figure 1
Substrate ubiquitination by RBX1-SCF E3 ubiquitin 
ligase: Cullin-1 at its N-terminus binds to Skp1 and an F-box 
protein, which recognizes protein substrates, and at its C-
terminus binds to RBX1. RBX1, on the other hand, binds to 
Cullin-1 using its N-terminus and an E2 ubiquitin conjugating 
enzyme using its C-terminal RING domain. Together, RBX1-
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essential gene for growth and development. Interestingly,
some similarity and difference exist between the species
with more than one family member of RBX1. For exam-
ple, death phenotype induced by disruption of ROC1a in
Drosophila or of RBX1 in mouse in the presence of their
family member ROC2 or RBX2 [10,12,13] clearly indi-
cated that these two RBX1 family members are not func-
tionally redundant and are likely to target different sets of
substrates during embryonic development. On the other
hand, the mechanisms responsible for reduced prolifera-
tion as a result of ROC1a/RBX1 disruption seem different
between Drosophila and mouse. In Drosophila, disruption
of ROC1a, causes lethality due to proliferation failure as a
result of accumulation of Ci (a Drosophila  ortholog of
mouse Gli2), a transcription factor that regulates Hedge-
hog signaling [10]. Whereas in mouse, disruption of RBX1
does not affect the levels of Gli2, but causes p27 accumu-
lation to suppress proliferation [12]. Furthermore,
although  RBX1-p27  double null embryos at E9.5 are
smaller than wild type littermates, no enhanced apoptosis
was detected using the TUNEL assay (unpublished data).
Thus, during mouse embryogenesis, RBX1  disruption
appears not to induce apoptosis. These observations in
normal tissues are strikely different from those seen in
human cancer cells (see below) in which RBX1 silencing
induces significant levels of apoptosis and senescence.
RBX1 in human cancer cell survival
RBX1-SCF E3 ubiquitin ligases regulate numerous cellular
processes. It is not surprising that their dysfunction is
associated with a variety of diseases including cancer [14].
For example, an oncogenic F-box protein Skp2, which
promotes p27 degradation, is overexpressed in a number
of human cancers [15], whereas a tumor suppressive F-
box protein FBW7, which promotes the degradation of
several proto-oncogenes, including c-Jun, c-Myc, cyclin E
and mTOR undergoes numerous cancer-associated muta-
tions [16]. To define potential roles of RBX1 in human
cancers, we recently measured expression of RBX1 in
human primary cancer tissues and in cancer cell lines with
different tissue origins. We found that RBX1 is overex-
pressed in a number of human primary cancer tissues,
including carcinoma of lung, liver, breast, colon, and
ovary, and in many cancer cell lines [17]. We then deter-
mined potential biological consequences of reducing
RBX1 levels via siRNA silencing. Significantly, RBX1
knockdown inhibited the growth of several human cancer
cell lines by sequential induction of G2-M arrest, senes-
cence and apoptosis. Further characterization revealed
that G2-M arrest is associated with accumulation of 14-3-
3σ and down-regulation of cyclin B1 and Cdc2, whereas
apoptosis is associated with modest accumulation of
PUMA and significant reduction of Bcl-2, Mcl-1, and sur-
vivin. Interestingly, senescence is p53/p21- and p16/pRB-
independent [17]. Recently a shRNA library-based func-
tional genomic screen also identified RBX1 as a growth
essential gene in a number of human cancer cell lines,
although no characterization was further pursued [18].
Mechanistic studies revealed that RBX1 silencing triggers
DNA damage response at the early stage, as demonstrated
by induced phosphoralytion of H2AX, Chk1 and Chk2
[17] (and unpublished data), which eventually leads to
G2-M arrest, followed by apoptosis and senescence. We
hypothesize that either or both sets of RBX1 substrates,
which start to accumulate upon RBX1 silencing, are likely
involved in the process, leading to phenotypic changes.
The first set includes oncogenes (e.g. c-Myc, c-Jun, cyclin
E/D), since oncogene activation triggers DNA damage
response to induce senescence and apoptosis under cer-
tain circumstances [19,20]. The second set of RBX1-cullin
substrates could be DNA replication proteins, such as Orc-
1 and Cdt-1, since the accumulation of DNA replication
proteins (e.g. Cdt-1) induces DNA rereplication stress and
Table 1: RBX1-Cullins E3 ubiquitin ligases and their substrates in mammals
Name Substrates References
RBX1/Cullin-1/SKP1/F-Box proteins e.g. p21, p27, p57, Cyclins A/D/E, E2F1, Cdc25A/B, PDCC4, FOXO1, Myc, p53, 
c-Jun, Notch 1/4, IκB, β-Catenin, Orc1, and many more. For near complete list, 
see cited references
[14,25,26]
RBX1/Cullin-2/Elongin BC/VHL e.g. HIF-α, TEL-JAK2 [27,28]
RBX1/Cullin-3/BTB-domain proteins e.g. MEI-1, Dishevelled (Dsh), Nrf2, RhoBTB2, topoisomeraseI-DNA complex, 
and caspase 8
[29-36]
RBX1/Cullin-4A/DDB1 e.g. p53, TSC2, Cdt1, c-Jun and Merlin [37-45]
RBX1/Cullin-5/elongin BC/BC-box proteins/SOCS e.g. Disabled-1 (Dab1) [46]
RBX1/Cullin-7/SKP1/Fbw8 e.g. Insulin receptor substrate 1 (IRS-1) [47]Cell Division 2009, 4:16 http://www.celldiv.com/content/4/1/16
Page 4 of 6
(page number not for citation purposes)
triggers DNA damage [21] (Fig 2B). Our laboratory is cur-
rently testing the hypothesis to further elucidate the mech-
anism(s) by which RBX1 silencing induces cancer cell
killing via induction of G2-M arrest, senescence and apop-
tosis.
It is rather clear that the mechanism responsible for early
embryonic lethality upon RBX1 disruption is quite differ-
ent from that responsible for cancer cell killing upon
RBX1 silencing, although it is not a typically paired com-
parison. Nevertheless, in mouse, RBX1 knockout leads to
p27 accumulation, reduced proliferation and prolonged
G1 arrest, whereas in human cancer cells, p27 accumula-
tion and G1 arrest were not observed upon RBX1 silencing
[17]. Future studies should be directed to determine if the
altered DNA damage response commonly seen in cancer
cells after RBX1 silencing can also be observed in RBX1-
p27 double null embryos and if so, its contribution to the
embryonic lethality in the later stages of development (Fig
2, crosstalk between panel A and B).
A working model for RBX1 targeting Figure 2
A working model for RBX1 targeting. (A) In mouse embryos. RBX1 disruption in mouse induces early embryonic 
lethality due to reduced proliferation as a result of p27 accumulation. Simultaneous deletion of p27 restores cell proliferation 
and causes a partial rescue of embryonic death by extending the embryo's life from E6.5 to E9.5. It is unclear, at the present 
time, if abnormal DNA damage response is involved in later stage death of RBX1/p27 double null embryos. (B) In human 
cancer cells: RBX1 silencing triggers DNA damage response and checkpoint controls via modulating the levels of oncogenes 
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Conclusion
The findings from our laboratory demonstrated that RBX1
is an essential gene not only for mouse development but
also for human cancer cell survival. The fact that RBX1 is
overexpressed in a number of human cancers suggests that
abnormal regulation of RBX1 is involved either in human
carcinogenesis or in the maintenance of the cancer cell
phenotype. Differential response to RBX1 disruption/
silencing between normal tissues (reduced proliferation,
but no induction of apoptosis during mouse embryogen-
esis) and cancer cells (enhanced cell killing) may provide
a reasonable therapeutic window for cancer cell-specific
killing via RBX1 targeting. Thus, future development of
siRNA-based therapy by RBX1 silencing or small molecule
inhibitors against RBX1 E3 ubiquitin ligases may hold
great promise for the treatment of human cancer [22-24].
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